A Case of Acute Myocardial Infarction during Chemotherapy of Advanced Rectal Cancer

Abstract

Background:Cetuximab and irinotecan, levoforinate, 5-FU (FOLFIRI) are administered to advanced colorectal cancer. Although this regimen is standardized for recurrent metastatic colorectal cancer, the merger of myocardial infarction is rare.Purpose:The aim of this study is consider factors of myocardial infarction that developed during chemotherapy of colorectal cancer.Method:We conduct a retrospective study of cases in which myocardial infarction develops during chemotherapy in colorectal cancer on the basis of medical records, nursing records and physiological function test results.Case:A 80-year-old man was in chemotherapy with cetuximab + FOLFIRI in outpatient with multiple lung metastasis diagnosis after rectal cancer surgery.Result:Three days after the 38th administration, the patient visited an emergency outpatient mainly with complaints of dyspnea and back pain. Electrocardiogram was a finding that the lower wall infarction is suspected. The patient of bi-aspirin oral administration and chest pain 10 mg of morphine hydrochloride was injected via intravenous drip infusion, and it was transferred to a specialized cardiovascular hospital.Emergency coronary angiography was performed in the diagnosis of acute myocardial infarction, and percutaneous coronary intervention was performed because the left anterior descending branch complete occlusion was recognized. After thrombus aspiration, the balloon was dilated, the stent was placed, and reperfusion was successfully completed. The patient was discharged on the 10th disease day.In this case, it is thought that cetuximab + FOLFIRI synergistically induced hyperthrombogenicity, coronary plaque erosion, and acute myocardial infarction.It may also be necessary for interventions such as monitoring of risks in daily living by the medical care provider and guidance on risk avoidance behaviors.brief background of the topic and significance of the study.Conclusion:In this case, it is thought that cetuximab + FOLFIRI synergistically induced hyperthrombogenicity, coronary plaque erosion, and acute myocardial infarction. It may also be necessary for interventions such as monitoring of risks in daily living by the medical care provider and guidance on risk avoidance behaviors.